Search

Mirati Therapeutics Inc

Open

SectorGezondheidszorg

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-0.05% downside

Nieuwssentiment

By Acuity

34%

66%

79 / 340 Rangschikking in Healthcare

Mirati Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 sep 2026, 23:56 UTC

News

Entergy Corp settled its 2025 forward sale agreements, delivering over 11 million shares for $913 million. Shares are higher in after-market trading.

2 sep 2026, 23:51 UTC

News

Mitek Systems Inc. won first place in the Image category of the 2026 LivDet-Face competition, boosting shares significantly higher in after-hours trading.

2 sep 2026, 23:51 UTC

News
Social Media

Uber Technologies Inc. shares are higher in after-market hours following its abrupt exit from Nigeria and plans to lay off over 3,000 employees globally.

2 sep 2026, 23:51 UTC

News

Revolution Medicines shares rise in after-market trading following positive Phase 1/2 data on RASONQUE for advanced RAS mutant non-small cell lung cancer.

2 sep 2026, 23:51 UTC

News

NWPX Infrastructure acquires Serpentix Conveyor, enhancing its wastewater treatment portfolio. Shares are trading higher in after-market hours following the announcement.

2 sep 2026, 23:46 UTC

News
Social Media

Zoom Communications appoints Jeff Epstein to its Board of Directors, effective immediately. Shares are trading higher in after-market hours amid leadership changes.

2 sep 2026, 23:41 UTC

News
Correlated Moves

nCino Inc will participate in the Piper Sandler Growth Frontiers Conference on September 16, 2026. Shares are higher in after-market trading.

2 sep 2026, 23:36 UTC

News

Phreesia shares declined after reporting second-quarter revenues of $129.5 million, while earnings per share of $0.03 missed expectations of $0.09.

2 sep 2026, 23:31 UTC

News

Genworth Financial announced a $500 million share repurchase program, with shares trading higher in after-market hours.

2 sep 2026, 23:31 UTC

News

Capital Southwest Corp increased its credit facility commitments to $595 million and extended the maturity to September 2031. Shares are higher in after-market trading.

2 sep 2026, 23:26 UTC

News

Sprinklr Inc shares are higher in after-market trading ahead of a meeting with DA Davidson on September 10, signaling potential strategic discussions.

2 sep 2026, 23:16 UTC

News
Correlated Moves

Cytokinetics Inc shares are trading lower after-market following its investor conference announcements, with Ionis Pharmaceuticals' decline possibly impacting sentiment in the sector.

2 sep 2026, 23:06 UTC

News
Social Media

JPMorgan Chase has reduced financing to Jane Street amid competition in the bond market, with shares trading near unchanged in after-market hours.

2 sep 2026, 23:06 UTC

News

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.

2 sep 2026, 23:06 UTC

News
Correlated Moves

The U.S. Justice Department disrupted the Sality botnet, linked to cryptocurrency theft, contributing to CrowdStrike's higher shares in after-market hours.

2 sep 2026, 23:02 UTC

News
Social Media
Event

Broadcom Inc. shares fell in after-market trading following third-quarter earnings. Fourth-quarter revenue guidance of $34.8 billion missed consensus expectations of $35.05 billion.

2 sep 2026, 23:02 UTC

News

C3.ai Inc reported a fiscal Q1 net loss of $92.8 million and projected second-quarter revenue below expectations, contributing to a decline in after-market hours.

2 sep 2026, 23:02 UTC

News
Event
Social Media

Five Below Inc. shares rose in after-market trading after strong Q2 earnings and a $600 million share repurchase program announcement. Revenue guidance was also raised.

2 sep 2026, 23:02 UTC

News
Social Media

Ultragenyx Pharmaceutical shares are lower in after-market hours following the failure of its Phase 3 Aspire study for apazunersen in Angelman syndrome.

2 sep 2026, 23:02 UTC

News
Social Media

Snowflake Inc's stock rose in after-market trading following strong Q2 results, with adjusted EPS of $0.62 and revenue of $1.55 billion exceeding expectations.

2 sep 2026, 23:02 UTC

News

Kroger Co shares traded lower in after-market hours following the appointment of Mark Ibbotson as Executive Vice President and Chief Store Operations Officer.

2 sep 2026, 23:02 UTC

News
Social Media

NetApp Inc. shares declined in after-market trading following its earnings report, despite record revenues of $2.03 billion and raised fiscal year 2027 guidance.

2 sep 2026, 23:02 UTC

News

Ollie's Bargain Outlet updated its fiscal year 2026 EPS guidance, projecting $4.570 to $4.650, exceeding the consensus estimate. Shares are higher in after-market trading.

2 sep 2026, 23:01 UTC

News
Social Media

AeroVironment secures a $464.8 million U.S. Army contract for laser systems, boosting after-market shares amid positive revenue growth projections of $2.7 billion by 2028.

2 sep 2026, 23:01 UTC

News

Mirion Technologies shares rose in after-market trading following CFO Brian Schopfer's purchase of 20,000 shares for $312,000, increasing his total ownership to 1.33 million shares.

2 sep 2026, 23:01 UTC

News

Matrix Service Co's stock is lower in after-market hours following a fourth-quarter earnings miss, with adjusted EPS at $0.16 against a $0.20 estimate.

2 sep 2026, 23:01 UTC

News

Argan Inc reported record revenue of $384 million and net income of $53.3 million in Q2, driving shares sharply higher in after-market hours.

2 sep 2026, 23:01 UTC

News
Social Media
Event

PVH Corp reported second-quarter adjusted EPS of $3.70, exceeding expectations. Shares are trading higher in after-market hours following the earnings announcement.

2 sep 2026, 23:01 UTC

News
Social Media

Methode Electronics reported a wider net loss of $11.4 million for Q1 fiscal 2027, leading shares to trade lower in after-market hours.

2 sep 2026, 23:01 UTC

News
Event
Social Media

Tillys Inc shares rose in after-hours trading following strong Q2 results, with EPS of $0.27 surpassing estimates and revenue of $163.5 million.

Peer Vergelijking

Prijswijziging

Mirati Therapeutics Inc Prognose

Koersdoel

By TipRanks

-0.05% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 58.67 USD  -0.05%

Hoogste 59 USD

Laagste 58 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Mirati Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

0

Buy

5

Hold

0

Sell

Sentiment

By Acuity

79 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

EBITDA

Operationele winst

$

Over Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
help-icon Live chat